Peripheral arterial disease is prevalent, associated with increased cardiovascular morbidity and mortality, and is underdiagnosed. Nevertheless, systematic efforts to provide early office-based peripheral arterial disease detection are not routinely implemented in office practice. The PARTNERS Program implemented the ankleÀbrachial index (ABI) measurement in primary care outpatient clinics in order to model practical dissemination of this technique and thus improve office-based peripheral arterial disease detection. The objective of this study was to identify clinician-defined factors that were perceived to foster acceptance of, or create barriers to, the use of the ABI in office practice. The ABI Utilization Survey was administered to primary care clinicians who participated in the PARTNERS Program, as well as to additional primary care clinicians who participated in the PARTNERS Preceptorship. The survey assessed six parameters: pre-and post-participation office ABI utilization; perceived clinical utility of the ABI; perceived value of the ABI data relative to other commonly used office disease detection methods; feasibility of implementing office-based ABI testing; definition of factors limiting utilization of the ABI in office practice; and the role of office staff in performing the ABI test. Survey data were obtained from 886 respondents. A total of 68% of respondents did not measure the ABI prior to participation in the PARTNERS Program. After Program participation, the frequency of office ABI use increased from 12% to 43% weekly and 13% to 39% monthly. The few participants who reported using the ABI only once a year (annually) did not significantly change after the program. Most clinicians believed that the ABI was useful in the diagnosis and management of both symptomatic (96%) and asymptomatic (89%) peripheral arterial disease. Moderate to major barriers to use of the ABI included time constraints (56%), lack of reimbursement (45%), and staff availability (45%). Nearly all (88%) clinicians believed that it was feasible to incorporate ABI into daily practice. Overall, most clinicians (57À75%) believed that ABI was equal to, or more useful, than other widely available and reimbursed screening tests in preserving their patients' health. In conclusion, the ABI was perceived by primary care clinicians to be a clinically useful diagnostic test. Limited reimbursement and time were identified as the primary barriers to its widespread use. Once learned, most clinicians stated that the ABI would continue to be frequently used in their office practice. The ABI is a simple peripheral arterial disease detection tool that can be successfully applied in primary care office practices.
Introduction
Peripheral arterial disease is common and will increase in prevalence in the USA due to the aging of the population. 1 Approximately one-third of patients who present with objective evidence of peripheral arterial disease have clinically significant limb symptoms, such as intermittent claudication, rest pain, or non-healing wounds. 2 Patients with claudication have approximately a 30% 5-year mortality rate. 3, 4 Those patients with peripheral arterial disease, but without classic claudication, also suffer a high mortality rate. 5 Current data also demonstrate that establishment of the peripheral arterial disease diagnosis, as for other manifestations of atherosclerosis, can be linked to effective therapeutic interventions. Use of these interventions has also been proven to improve cardiovascular ischemic event rates and quality of life. 2, 6, 7 Because the high burden of disease with its associated risk for poor ischemic outcomes can be attenuated by appropriate interventions, office-based detection may improve public health. 8À10 The ankleÀbrachial index (ABI) is an objective diagnostic method that serves as the recognized standard to establish the peripheral arterial disease diagnosis. An abnormal ABI has a high sensitivity and specificity for peripheral arterial disease, as validated by contrast angiographic methods. 10À13 The ABI value is predictive of limb survival and short-and long-term patient survival. 14 All individuals with an ABI of < 0.90 are at increased risk of cardiovascular ischemic events and face a threefold increased risk of total mortality compared with age-matched nonperipheral arterial disease individuals. The TransAtlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC) concluded that the ABI is the most useful non-invasive test to detect peripheral arterial disease. 14 The clinical utility of the ABI has been extended from its original use in epidemiologic surveys to many relevant clinical populations by several prospective investigations. Newman et al evaluated the relationship between an abnormal ABI (defined as an ABI < 0.9) and subsequent cardiovascular morbidity and mortality in 1537 individuals with systolic hypertension. 3 After adjustment for baseline cardiovascular disease and other cardiovascular risk factors, a minimally abnormal ABI was associated with a relative risk of 4.1 for total mortality and of 2.4 for cardiovascular morbidity and mortality. These results indicate that even small decrements in the ABI provide valuable data that predict both morbidity and mortality among older patients with systolic hypertension. 3 Similarly, Vogt et al studied 1492 women !65 years of age who were participating in the Multicenter Study of Osteoporotic Fractures. An ABI of 0.9 was independently associated with increased mortality in the entire group and among women free of cardiovascular disease at baseline. 15 The efficacy of use of the ABI within large-volume clinical primary care practices was assessed in the PAD Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program, providing an opportunity to assess clinician perceptions regarding its utility. 1 Thus, the current study was designed: (1) to measure the perceptions of a large primary care clinician cohort regarding the clinical utility of office-based peripheral arterial disease detection via use of the ABI; (2) to identify perceived barriers to prior use of the ABI; and (3) to determine whether the ABI educational intervention was effective in increasing reported use of the ABI in office practice by clinicians who participated in either the PARTNERS Program or in the subsequent PARTNERS Preceptorship.
Methods
The PARTNERS Program utilized the ABI measurement to evaluate 6979 patients in 350 primary care office practices in 25 cities nationwide in mid-1999 in order to define the prevalence of peripheral arterial disease in a targeted, high-risk population. 1 A primary objective of this Program was to determine the feasibility of detecting peripheral arterial disease in the primary care setting and to evaluate the level of physician and patient awareness of the peripheral arterial disease diagnosis. Following completion of the PARTNERS Program, the techniques utilized to teach the ABI technique were extended in a PARTNERS Preceptorship program. The Preceptorship enrolled additional primary care physicians, nurse practitioners, physician's assistants, and nurses nationwide from high-volume primary care practices in 87 Preceptorship programs that were held in 56 cities. Participants were not, therefore, selected randomly within each region, but were chosen primarily based on practice volume and presence of multiple practitioners in the office. Selection led to targeted inclusion of practices that cared for adult (versus pediatric and geriatric) populations. The Preceptorship consisted of a 2 1 2 -hour didactic educational session regarding peripheral arterial disease, linked to a 'hands-on' training session in which participants learned use of the ABI technique. In combination with the original PARTNERS Program, the Preceptorship provided a substantial population of primary care clinicians in whom perceptions and experience regarding use of the ABI could be effectively surveyed.
The ABI Utilization Survey was developed to assess the following six parameters: pre-and post-participation office utilization of the ABI; perceived clinical utility of the ABI among different patient groups; perceived value of the ABI data relative to other commonly used office disease detection methods; feasibility of implementing office-based ABI testing; definition of factors limiting utilization of the ABI in office practice; and the role of office staff in performing the ABI test. The questionnaire used in the study is included in the Appendix. The Institutional Review Boards at participating institutions and office practices approved the study. The questionnaire was created by the PARTNERS Steering Committee and administered to the PARTNERS investigators at the final investigators' meeting, which was held 3 months after Program study completion in January, 2000. Questionnaires were also mailed to and collected from those investigators who did not attend the meeting. The same questionnaire was given to each PARTNERS Preceptorship participant and was returned by mail within 1 month of the meetings, which were held from May to December, 2000.
Data were analyzed using descriptive statistics and nonparametric chi-squared analyses. Results for PARTNERS Program investigators and Preceptorship participants are reported individually. To evaluate differences between groups, responses to the perceived limitations were recoded into two categories (no or minor limitation versus moderate or major limitation) and then analyzed using chi-squared analysis.
Results

Professional training of clinician participants
The ABI Utilization Survey was administered to 700 clinicians in the PARTNERS Program (50% physician, 50% other clinicians) and to 2630 clinicians in the Preceptorship (85% physician, 15% other clinicians). Overall response rates were 38% for the PARTNERS clinicians and 24% for the Preceptorship participants. The professional training of the respondents is summarized in Table 1 .
ABI utilization in office practice
Prior to participation in the PARTNERS Program or Preceptorship, 69% and 67% of participants, respectively, indicated that they had never measured the ABI in the office practice setting ('never use'). Only small percentages of respondents reported measuring the ABI annually, monthly or weekly ( Figure 1A ). Respondents indicated that Program or Preceptorship participation resulted in an increased use of the ABI in their clinical practice. Respondents in the two programs reported a decline in 'never use' to 14% and 11%, respectively, whereas there were dramatic increases in ABI utilization monthly (from 12% to 46%, and from 13% to 35%, respectively) and weekly (from 13% to 35%, and from 12% to 46%, respectively) ( Figure 1B ). The few participants who reported using the ABI only once a year (annually) did not significantly change after the program.
Perceived utility of the ABI for the care of peripheral arterial disease In order to determine the perceived utility of the ABI in clinical practice, participants were asked, 'How useful have you found the ABI to be in the diagnosis and clinical management of asymptomatic or symptomatic patients with peripheral arterial disease?' Clinicians indicated that measurement of the ABI was clinically useful for both asymptomatic and symptomatic patients ( Table 2) . For asymptomatic patients, 89% of the respondents reported that the ABI was either moderately or very useful. For symptomatic patients, 96% of the respondents reported that the ABI was either moderately or very useful.
Relative importance of ABI testing compared with other disease screening tests
Clinicians were asked to compare the usefulness of the ABI with other commonly performed disease screening tests. This question was designed to compare the perceived utility of the ABI with other frequently ordered diagnostic tests for disorders that are prevalent in office practice, such as breast cancer (by mammography), hyperlipidemia (by the fasting lipid profile), prostate cancer (by measurement of prostate-specific antigen, PSA), coronary artery disease (by use of standard exercise treadmill testing), and colorectal cancer (by measurement of stool occult blood). Nearly half of all respondents indicated that the ABI was essentially equally useful compared with these other testing strategies. For example, approximately half of respondents in both the PARTNERS Program and PARTNERS Preceptorship described the mammogram and lipid evaluation as 'similarly useful' or 'more useful' compared with the ABI in office practice. These results are summarized in Table 3 .
Performance of the ABI À time requirements, reporting, and recording of results The great majority of respondents (86%) reported that the ABI procedure could be performed in 15 minutes or less. Nearly all respondents indicated that, when performed, they included the ABI data in the medical record (94%) and always reported the results of ABI testing to the patient (86%).
Performance of the ABI À staff involvement Office practices can be organized using a range of personnel to offer the ABI in primary care practice.
In the original PARTNERS Program, each office was permitted to assign the personnel they deemed most effective in performing the ABI, and Preceptorship participants were comparably asked to report how the ABI was performed in their office practice. Relatively few of the respondents (33%) indicated that the physician alone performed the ABI test procedure. An additional 20% of respondents indicated that the physician and another staff member performed the ABI. A total of 38% of respondents indicated that a nurse or nurse practitioner performed the ABI, either alone or in addition to other office staff. The medical assistant performed the ABI in 12% of office practices.
Feasibility and limitations of ABI testing
When evaluating the feasibility of incorporating ABI into daily practice, 90% and 88% of respondents in the PARTNERS Program and Preceptorship, respectively, indicated that the ABI was either very or moderately feasible ( Figure 2 ). Participants were also asked to consider the factors that limit office utilization of the ABI (Figure 3 ). Time constraints (56%), reimbursement (45%), and staff availability (45%) were identified by the greatest percentage of respondents as being factors that represented a moderate or major limitation to utilization of the ABI. Among all the factors considered (staff training, staff availability, availability of equipment, patient willingness, space to perform the ABI, clinical significance, reimbursement, and time constraints), time constraints was the only factor considered either a moderate or major limitation by a majority of respondents. Most respondents considered each of the other factors to be either no limitation or only a minor limitation.
Differences between program and preceptorship participants
This survey was designed to permit assessment of the impact of a more intense participation in ABI teaching and use (the PARTNERS Program) and a briefer educational intervention (the Preceptorship). Thus, it is notable that there were several differences observed between PARTNERS Program investigators and Preceptorship participants in their perceptions of the limitations or barriers to using the ABI in clinical practice. PARTNERS Program investigators were more likely than Preceptorship participants to perceive reimbursement for performing the ABI as a moderate or major limitation (51% vs 43%; v 2 ¼ 4.46, p < 0.05). PARTNERS Program investigators were also more likely to perceive patient willingness as a moderate or major limitation (12% vs 4%; v 2 ¼ 18.20, p < 0.001); however, this factor was perceived as no limitation or a minor limitation by the majority of both groups. Preceptorship participants were more likely to perceive training of staff as a moderate or major limitation than the PARTNERS Program investigators (32.3% vs 21%; v 2 ¼ 10.70, p ¼ 0.001), and were also more likely to perceive a lack of a Doppler device as a moderate or major limitation (15.2% vs 8%; v 2 ¼ 8.80, p ¼ 0.01). Despite these differences, the majority of both groups viewed lack of Doppler devices and associated equipment as no limitation or a minor limitation. The majority of both groups viewed time as a moderate or major limitation to routine performance of the ABI in clinical practice. There were also differences between PARTNERS Program investigators and Preceptorship participants in the perceived utility of the ABI when compared with other (Table 3) . PART-NERS investigators were more likely to consider the ABI similarly useful to lipid assessment (v 2 ¼ 8.60, p< 0.05), and to PSA assessment (v 2 ¼ 12.80, p< 0.01), than Preceptorship participants. PARTNERS Program investigators were more likely than Preceptorship participants to evaluate the ABI as more useful when compared with a standard exercise stress test (v 2 ¼ 6.40, p< 0.05) and assessment of stool occult blood (v 2 ¼ 12.10, p< 0.01) .
The data were also analyzed to determine whether there were differences in survey responses between physician and other-clinician participants. There were no differences between these groups in perceived limitations to performing the ABI or in the perceived feasibility of performing the ABI in practice. There were, however, differences between physicians and other providers in the perceived usefulness of the ABI when compared with other commonly performed screening procedures. The other-clinician group was more likely to perceive the ABI as equally useful compared with mammography (61.3% and 43%, respectively; v 2 ¼ 6.30, p < 0.001), lipid assessment (59% and 47%, respectively; v 2 ¼ 7.42, p ¼ 0.025), PSA measurement (69% and 48%, respectively; v 2 ¼ 23.06, p < 0.001), and assessment of stool occult blood (71% and 54%, respectively; v 2 ¼ 13.59, p < 0.001). There were no differences between these groups in perceived usefulness of ABI when compared with standard exercise testing.
Discussion
The results of this ABI Utilization Survey demonstrate that a targeted educational initiative can have significant impact on use of the ABI in clinical practice, which could offer dramatic benefits to improve peripheral arterial disease diagnosis. The respondents reported an increased use of the ABI as an assessment tool, and these data suggest that this use was based on a heightened awareness of the importance of peripheral arterial disease diagnosis, especially among patients at risk, even if those patients were currently asymptomatic. The greatest change in measuring ABI was in the group who reported never before using the ABI in practice whereas no significant change was reported in those few who only measured the ABI once a year.
One of the most intriguing results of this survey was assessment of the perceived clinical utility of the ABI compared with other 'accepted' procedures that are widely used to detect other important diseases. These data demonstrate that a large fraction (approximately half) of clinicians considered the ABI to be as useful in primary care practice as mammography, lipid measurement, PSA assessment, exercise stress testing, and stool occult blood testing. If the ABI is considered by respondents to be so useful by clinicians in practice, then identification of barriers to its wider use is important.
This survey provides insight concerning the logistical considerations that facilitate or impede use of office-based ABI assessments. The majority of respondents identified time limitations as a major barrier to the routine use of the ABI in office practice. This identification of time as a significant barrier to ABI use is notable despite the fact that these respondents identified that the ABI could usually be completed in 15 minutes or less. This provides insight into the time constraints that exist in current primary care practices and how such constraints may impede deployment of new testing strategies in this setting.
Differences between PARTNERS Program investigators and Preceptorship participants could be explained by the differences in the intensity of educational intervention and hands-on experience between the two groups and the timing of completion of the survey. The PARTNERS investigators were surveyed many months following the completion of the PART-NERS study. These respondents had a more intensive educational intervention and had more time to develop practical experience in the use of the ABI in practice. This may have resulted in an increased appreciation for the ABI as a clinical diagnostic tool, as evidenced by a greater likelihood to evaluate the ABI as equally useful when compared with lipid, PSA, standard exercise testing, and stool occult blood assessment. This increased experience may also have raised practical concerns about limitations to routine performance of the ABI in the clinical setting, such as the ability to be reimbursed for the procedure. The PARTNERS investigators' increased perception of patient willingness as a limitation may have been associated with their requirement to request informed consent for patient participation in the PARTNERS investigation. The demands of the original investigation, which included chart review, patient interview, and questionnaire completion À rather than just the ABI testing À distinguished the experience of the investigators from that of Preceptorship participants. The increased practical experience of the PARTNERS investigators may also have contributed to their perception that staff training and availability were less of a limitation than for Preceptorship participants.
Physician and non-physician respondents were similar in their evaluations of the feasibility and potential limitations of utilizing the ABI in the office setting. Nonphysician respondents were somewhat more likely than physicians to rate the ABI as similarly useful when compared with other commonly performed screening tests. The physician respondents were more likely to rate several of these tests as more useful than the ABI. How professional training alters perception of test value has rarely been explored and may warrant further study.
These data may provide clues for future strategies to improve the use of the ABI as a practical diagnostic tool in the office setting. Performance of the ABI requires an investment of time from office staff. While the ABI measurement has been deemed similar to measurement of the arm blood pressure (and therefore not meriting reimbursement), the ABI does require more time than is allotted for additional components of the office physical examination. This barrier to ABI use could be surmounted by patient referral to vascular laboratories. This strategy would increase the total national costs of peripheral arterial disease detection and may well be associated with increasing health disparity in peripheral arterial disease detection to patients who are insured, who have time for the referral, and who are willing to comply with a second appointment. Alternatively, the barrier could be surmounted by use of office-based vascular laboratories. This strategy may limit use of the ABI to office practices willing to invest in such equipment.
There is an additional clinical benefit to performance of the ABI in office practice, and to its chart documentation and reporting of the result to the patient. As noted in the original PARTNERS report, patient awareness of the peripheral arterial disease diagnosis is low. 1 Performance of the ABI and its immediate discussion with the patient is likely to be associated with increased patient awareness of the diagnosis and its implications.
Study limitations
These data demonstrate that clinician educational programs can be successful in altering peripheral arterial disease care standards if the intervention includes training of office staff (both physicians and nurses). Nevertheless, this survey evaluated ABI utilization in a relatively small convenience sample of clinicians during a relatively short period following the educational intervention. Further, the relatively low response rates could result in reporting bias. We therefore do not know if our findings would be generalizable to the clinicians who did not respond to the survey. This limitation acknowledged, this is the largest extant survey of primary care clinician attitudes regarding ABI use.
Another potential barrier to adoption of the ABI not evaluated in this study was a lack of lower extremity peripheral arterial disease treatment guidelines, although these are anticipated in the near future. It is not known whether office-based peripheral arterial disease detection was altered over a longer, more clinically meaningful time frame. There are no data that yet demonstrate that cardiovascular outcomes are altered when the ABI test is applied to a targeted population. Further research would be required to determine whether use of the ABI in clinical practice would be sustained following a more intense education and training program, to determine what educational elements contribute to long-term intensification of peripheral arterial disease treatment, and how these might improve clinical outcomes.
Summary and conclusions
In conclusion, this study indicates that the ABI, traditionally used as an epidemiologic tool or as a component of vascular laboratory evaluation, is perceived by primary care physicians as a clinically useful tool for use in office practice. Acceptance of this role for the ABI was associated with training in its use in a program of peripheral arterial disease education and ABI training. The results from this study provide evidence that clinicians accept their role to diagnose peripheral arterial disease; that they appreciate that this simple peripheral arterial disease detection tool can successfully be applied in primary care office practices; and that peripheral arterial disease detection is valued, despite current barriers to its wider use. 
